Lantern Pharma to Showcase AI-Driven Glioblastoma Drug Development at Boston Summit
Event summary
- Lantern Pharma CEO Panna Sharma to present at the 7th Glioblastoma Drug Development Summit in Boston on February 19, 2026.
- Presentation will highlight AI-driven insights from RADR® platform for STAR-001, a brain-penetrant therapeutic candidate.
- STAR-001 has received FDA Orphan Drug and Rare Pediatric Disease Designations for ATRT.
- Lantern's subsidiary Starlight Therapeutics is advancing clinical development for CNS cancers.
The big picture
Lantern Pharma's presentation underscores the growing role of AI in precision oncology, particularly for aggressive brain cancers with high unmet needs. The company's focus on biomarker identification and combination therapies aligns with broader industry trends toward targeted, data-driven drug development. The strategic separation of CNS-focused assets into Starlight Therapeutics suggests a potential spin-off or partnership play to unlock value.
What we're watching
- AI Integration
- How Lantern's RADR® platform will affect the pace of neuro-oncology drug development.
- Regulatory Advantage
- Whether FDA designations for STAR-001 will accelerate clinical timelines or partnership opportunities.
- Commercialization Path
- The pace at which Starlight Therapeutics advances CNS cancer therapies to market.
Related topics